Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Parra-Ruiz

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
The Journal of Antimicrobial Chemotherapy|July 17, 2012
Activity of linezolid and high-dose daptomycin, alone or in combination, in an in vitro model of Staphylococcus aureus biofilmJorge Parra-Ruiz, Alejandra Bravo-Molina, Alejandro Peña-Monje, et al.
BMC Microbiology|November 1, 2015
In vitro efficacy of daptomycin and teicoplanin combined with ethanol, clarithromycin or gentamicin as catheter lock solutionsDiego Parra, Alejandro Peña-Monje, Nieves María Coronado-Álvarez, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|March 5, 2013
[Update on hepatitis C therapy. New drugs, treatment response monitoring and emergence of resistance]Natalia Chueca Porcuna, Marta Alvarez Estévez, Jorge Parra Ruiz, et al.
The Annals of Pharmacotherapy|January 27, 2004
Comment: Reasons for early abacavir discontinuation in HIV-infected patientsJorge Parra-Ruiz, Mariela Martínez-Ramírez, Leopoldo Muñoz-Medina, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|April 20, 2011
[Efficacy and safety of high dose (≥8 mg/kg/day) daptomycin]Jorge Parra-Ruiz, Alejandro Peña-Monje, Cristina Tomás-Jiménez, et al.
Stroke|August 30, 2003
Stroke prevention: indapamide, a forgotten option?Jorge Parra Ruiz, Leopoldo Muñoz Medina, Francisco Miras Parra, et al.
AIDS (London, England)|May 20, 2014
Protease inhibitor monotherapy is not associated with increased viral replication in lymph nodesDavid Vinuesa, Jorge Parra-Ruiz, Natalia Chueca, et al.
Medicina Clinica (English Ed.)|May 31, 2022
Benefits of early use of high-flow-nasal-cannula (HFNC) in patients with COVID-19 associated pneumoniaLaura García-Pereña, Violeta Ramos Sesma, María Lucía Tornero Divieso, et al.
Medicina Clinica|July 5, 2021
[Benefits of early use of high-flow-nasal-cannula (HFNC) in patients with COVID-19 associated pneumonia]Laura García-Pereña, Violeta Ramos Sesma, María Lucía Tornero Divieso, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|July 29, 2014
[Characteristics of tuberculosis in the immigrant population in South Granada Health Area]Concepción Morales-García, Jorge Parra-Ruiz, Beatriz Valero-Aguilera, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
The Journal of Antimicrobial Chemotherapy|July 17, 2012
Activity of linezolid and high-dose daptomycin, alone or in combination, in an in vitro model of Staphylococcus aureus biofilmJorge Parra-Ruiz, Alejandra Bravo-Molina, Alejandro Peña-Monje, et al.
BMC Microbiology|November 1, 2015
In vitro efficacy of daptomycin and teicoplanin combined with ethanol, clarithromycin or gentamicin as catheter lock solutionsDiego Parra, Alejandro Peña-Monje, Nieves María Coronado-Álvarez, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|March 5, 2013
[Update on hepatitis C therapy. New drugs, treatment response monitoring and emergence of resistance]Natalia Chueca Porcuna, Marta Alvarez Estévez, Jorge Parra Ruiz, et al.
The Annals of Pharmacotherapy|January 27, 2004
Comment: Reasons for early abacavir discontinuation in HIV-infected patientsJorge Parra-Ruiz, Mariela Martínez-Ramírez, Leopoldo Muñoz-Medina, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|April 20, 2011
[Efficacy and safety of high dose (≥8 mg/kg/day) daptomycin]Jorge Parra-Ruiz, Alejandro Peña-Monje, Cristina Tomás-Jiménez, et al.
Stroke|August 30, 2003
Stroke prevention: indapamide, a forgotten option?Jorge Parra Ruiz, Leopoldo Muñoz Medina, Francisco Miras Parra, et al.
AIDS (London, England)|May 20, 2014
Protease inhibitor monotherapy is not associated with increased viral replication in lymph nodesDavid Vinuesa, Jorge Parra-Ruiz, Natalia Chueca, et al.
Medicina Clinica (English Ed.)|May 31, 2022
Benefits of early use of high-flow-nasal-cannula (HFNC) in patients with COVID-19 associated pneumoniaLaura García-Pereña, Violeta Ramos Sesma, María Lucía Tornero Divieso, et al.
Medicina Clinica|July 5, 2021
[Benefits of early use of high-flow-nasal-cannula (HFNC) in patients with COVID-19 associated pneumonia]Laura García-Pereña, Violeta Ramos Sesma, María Lucía Tornero Divieso, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|July 29, 2014
[Characteristics of tuberculosis in the immigrant population in South Granada Health Area]Concepción Morales-García, Jorge Parra-Ruiz, Beatriz Valero-Aguilera, et al.
Pageof 3